trb_welcome.jpg

 

The mission of TRB Chemedica Group is to develop innovative and patented pharmaceutical products and medical devices in niche therapeutic areas: rheumatology, ophthalmology and neurology.


eye_pic.jpg

In recent years the nosology of Dry Eye has greatly changed. Professor Baudouin, MD, PhD from National Ophthalmologiy Hospital XV-XX, Vision Institute of Paris explains through this didactic video the complexity of the Dry Eye disease. Moving beyond the simple name of Dry Eye syndrome, we now consider the condition to be Dry Eye disease, insisting on the lack of tears, the lacrimal inflammation and hyperevaporation leading to self-sustaining loops of neurogenic and palpebral inflammations.

View the video


diacerein_logo.gif

Oral inhibition of interleukin-1 in the treatment of osteoarthritis.

DIACEREIN is indicated for the specific, long-term oral treatment of degenerative joint diseases (osteoarthritis and related diseases). DIACEREIN has a unique mode of action through inhibition of the production and activity of interleukin-1, the key mediator in the progression of osteoarthritis.

DIACEREIN is effective in reducing pain and functional impairment, the major symptoms of OA, and has shown structure-modifying effects with good gastrointestinal tolerability.

 

diacerein_box01.jpg

Diacerein is sold under the tradenames ARTRODAR®, ARTRODARIN®, ARTROLYT®, ARTRIZONA®, GALAXDAR®, GLIZOLAN®, VERBORIL®.

pdfDIACEREIN Brochure
trb_lock.gif Doctor information
Distributors
trb_contact.gifContacts

News-Events
 
 
  • English